158 related articles for article (PubMed ID: 21187490)
1. Up-regulation of glypican-3 in human hepatocellular carcinoma.
Suzuki M; Sugimoto K; Tanaka J; Tameda M; Inagaki Y; Kusagawa S; Nojiri K; Beppu T; Yoneda K; Yamamoto N; Ito M; Yoneda M; Uchida K; Takase K; Shiraki K
Anticancer Res; 2010 Dec; 30(12):5055-61. PubMed ID: 21187490
[TBL] [Abstract][Full Text] [Related]
2. [Expression of glypican-3 mRNA in hepatocellular carcinoma and its significance].
Ban KC; Cao J; Ou C; Yang C; Su JJ; Li Y; Xue HF; Duan XX
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):281, 285. PubMed ID: 15850517
[No Abstract] [Full Text] [Related]
3. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
6. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
8. A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.
Maurel M; Jalvy S; Ladeiro Y; Combe C; Vachet L; Sagliocco F; Bioulac-Sage P; Pitard V; Jacquemin-Sablon H; Zucman-Rossi J; Laloo B; Grosset CF
Hepatology; 2013 Jan; 57(1):195-204. PubMed ID: 22865282
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
Yorita K; Takahashi N; Takai H; Kato A; Suzuki M; Ishiguro T; Ohtomo T; Nagaike K; Kondo K; Chijiiwa K; Kataoka H
Liver Int; 2011 Jan; 31(1):120-31. PubMed ID: 20964802
[TBL] [Abstract][Full Text] [Related]
11. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis.
Saito S; Ojima H; Ichikawa H; Hirohashi S; Kondo T
Cancer Sci; 2008 Dec; 99(12):2402-9. PubMed ID: 19038010
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
15. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.
Huang N; Lin J; Ruan J; Su N; Qing R; Liu F; He B; Lv C; Zheng D; Luo R
FEBS Lett; 2012 Mar; 586(6):884-91. PubMed ID: 22449976
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
17. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma.
Chen M; Li G; Yan J; Lu X; Cui J; Ni Z; Cheng W; Qian G; Zhang J; Tu H
Clin Chim Acta; 2013 Aug; 423():105-11. PubMed ID: 23643963
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma.
Kondoh N; Shuda M; Tanaka K; Wakatsuki T; Hada A; Yamamoto M
Anticancer Res; 2001; 21(4A):2429-33. PubMed ID: 11724303
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
20. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Fuke H; Shiraki K; Sugimoto K; Tanaka J; Beppu T; Yoneda K; Yamamoto N; Ito K; Masuya M; Takei Y
Biochem Biophys Res Commun; 2007 Nov; 363(3):738-44. PubMed ID: 17904524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
